MOLECULARHEALTH
LIVE

Serial Number

85583366

Owner

Molecular Health GmbH

Attorney

Robert S. Weisbein

Filing Date

Mar 29, 2012

Add to watchlist:

No watchlists yet
View on USPTO

MOLECULARHEALTH Trademark

Serial Number: 85583366 • Registration: 4975047

MOLECULARHEALTH is a trademark filed by Molecular Health GmbH on March 29, 2012. The trademark is classified under Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Molecular Health GmbH (44 trademarks)

Belfortstr. 2
Heidelberg 69115 , DE

Entity Type: 03

Molecular Health AG (6 trademarks)

Dufourstr. 25
4010 Basel , CH

Entity Type: 99

Trademark Details

Filing Date

March 29, 2012

Registration Date

June 7, 2016

Goods & Services

Providing an online database featuring medical information and diagnostic, prophylactic and therapeutic properties of pharmaceuticals, and genomic information as it relates to medical diagnosis and treatment; pharmaceutical consulting services in pharmaceuticals and genetics in relation to patient medical treatment options; medical consulting services with respect to the treatment and diagnosis of individuals in the fields of clinical pharmacology and the analysis of dose effect relationships for treatment purposes; providing pharmaceutical information, namely, information about drug safety and drug compatibility in relation to cancer therapy and the treatment of individual patients; medical consulting services in the fields of patient treatment and treatment protocols

Data collection for medical and scientific research purposes, namely, the collection and systematic sorting of clinical and patient data comprising patient-specific molecular and genomic data, patient specific clinical data and scientific clinical studies; data collection for medical and scientific research purposes, namely, the collection of mathematic and statistical data, clinical data, patient data and data of clinical studies relating to clinical response to drug treatments; providing medical and scientific research information and scientific consulting in the fields of pharmaceutical side effects, genomics, biological medicine and translational medicine; providing an online database comprised of medical, pharmaceutical, biological and genomic information for scientific research purposes; providing an online searchable database in the fields of biological medical, translational medicine, interventional epidemiology, bioinformatics, clinical information technology, genomic data and genomic sequence analysis for scientific research purposes; design and development of computer software in the fields of biology, medicine, and bioinformatics; design and development of computer software for integration of patient specific data, molecular test results, clinical studies and scientific results; providing online non-downloadable computer software for use by healthcare professionals for medical treatment research; design and development of databases featuring biomarker data; providing an online searchable database for clinical and scientific research in the field of medical, diagnostic and treatment research; Software as a Service (SAAS) services featuring software for providing information for patient treatment by enabling the retrieval and correlation of genomic data, drug protocols, clinical profiling and integration and statistical analysis of data for medical purposes; providing online non-downloadable software for retrieval and correlation of genomic data, drug protocols, clinical profiling and integration and statistical analysis of data for medical diagnostic and treatment research purposes; medical research and scientific research and scientific consulting services, namely, designing and conducting drug safety and dosage assessment and drug compatibility studies in the field of cancer therapy for others; consulting services in the field of pharmaceuticals and genetics, namely, conducting drug safety and dosage assessment and in drug compatibility studies in the field of cancer treatment therapy for others relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; Providing online non-downloadable computer software for use by healthcare professionals for medical diagnostics

Filing History

COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Jun 8, 2025 REM2
NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
Jun 7, 2023 NAS8
REGISTERED - SEC. 8 (6-YR) ACCEPTED
Jun 7, 2023 8.OK
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Jun 5, 2023 APRE
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Dec 17, 2022 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Dec 17, 2022 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Dec 17, 2022 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Dec 17, 2022 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Dec 17, 2022 COAR
TEAS SECTION 8 RECEIVED
Dec 6, 2022 ES8R
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Jun 7, 2021 REM1
REGISTERED-SUPPLEMENTAL REGISTER
Jun 7, 2016 R.SR
LAW OFFICE PUBLICATION REVIEW COMPLETED
May 5, 2016 PREV
APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER
Apr 28, 2016 CNTA
EXAMINER'S AMENDMENT ENTERED
Apr 27, 2016 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Apr 27, 2016 GNEN
EXAMINERS AMENDMENT E-MAILED
Apr 27, 2016 GNEA
EXAMINERS AMENDMENT -WRITTEN
Apr 27, 2016 CNEA
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Apr 26, 2016 ZZZX
WITHDRAWN FROM PUB - OG REVIEW QUERY
Mar 29, 2016 PBCR
LAW OFFICE PUBLICATION REVIEW COMPLETED
Mar 11, 2016 PREV
APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER
Mar 8, 2016 CNTA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 4, 2016 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 3, 2016 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 3, 2016 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Dec 21, 2015 GNRN
NON-FINAL ACTION E-MAILED
Dec 21, 2015 GNRT
NON-FINAL ACTION WRITTEN
Dec 21, 2015 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 9, 2015 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 9, 2015 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 30, 2015 TROA
ASSIGNED TO EXAMINER
Oct 19, 2015 DOCK
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 31, 2015 GNRN
NON-FINAL ACTION E-MAILED
May 31, 2015 GNRT
NON-FINAL ACTION WRITTEN
May 31, 2015 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
May 6, 2015 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 6, 2015 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Apr 28, 2015 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Oct 29, 2014 GNS2
INQUIRY TO SUSPENSION E-MAILED
Oct 29, 2014 GNSI
SUSPENSION INQUIRY WRITTEN
Oct 29, 2014 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Oct 7, 2014 RCCK
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Aug 20, 2014 ASGN
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Apr 7, 2014 GNS3
LETTER OF SUSPENSION E-MAILED
Apr 7, 2014 GNSL
SUSPENSION LETTER WRITTEN
Apr 7, 2014 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 20, 2014 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 20, 2014 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Mar 14, 2014 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Oct 4, 2013 GNS2
INQUIRY TO SUSPENSION E-MAILED
Oct 4, 2013 GNSI
SUSPENSION INQUIRY WRITTEN
Oct 4, 2013 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Sep 19, 2013 RCCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Mar 18, 2013 GNS3
LETTER OF SUSPENSION E-MAILED
Mar 18, 2013 GNSL
SUSPENSION LETTER WRITTEN
Mar 18, 2013 CNSL
EXAMINER'S AMENDMENT ENTERED
Mar 7, 2013 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Mar 7, 2013 GNEN
EXAMINERS AMENDMENT E-MAILED
Mar 7, 2013 GNEA
EXAMINERS AMENDMENT -WRITTEN
Mar 7, 2013 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 31, 2013 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 31, 2013 CRFA
ASSIGNED TO LIE
Jan 24, 2013 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 22, 2013 TROA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jan 22, 2013 TCCA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 22, 2012 GNRN
NON-FINAL ACTION E-MAILED
Jul 22, 2012 GNRT
NON-FINAL ACTION WRITTEN
Jul 22, 2012 CNRT
ASSIGNED TO EXAMINER
Jul 10, 2012 DOCK
NOTICE OF PSEUDO MARK MAILED
Apr 5, 2012 MPMK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 4, 2012 NWOS
NEW APPLICATION ENTERED
Apr 2, 2012 NWAP